Because of high protein-binding capacity, clinically significant excretion into breast milk is unlikely. However, both the mother and the infant would benefit of the use of a better-known alternative drug that would be safer while breastfeeding, especially in the neonatal period and in case of prematurity. In spite of a low excretion into breast milk, it has been described a case of severe apnea in a 12 days old infant. A causal connection between those features and this drug has not been clearly defined (Briggs 2011, p. 410). It is licensed for use in children from 6 months of age as intestinal antispasmodic and treatment of Familial Mediterranean Fever, so there would be less risky when used by the breastfeeding mother.